Gene content    
EPHB2 ( by HUGO)
EPH Receptor B2
Tumor suppressor gene
EPH Receptor B2
DRT
EPHT3
ERK
Developmentally-Regulated Eph-Related Tyrosine Kinase
ELK-Related Tyrosine Kinase
EPH Tyrosine Kinase 3
Renal Carcinoma Antigen NY-REN-47
Tyrosine-Protein Kinase Receptor EPH-3
Tyrosine-Protein Kinase TYRO5
EK5
EPH-Like Kinase 5
EC 2.7.10.1
CAPB
PCBC
EphB2
Hek5
Tyro5
Ephrin Type-B Receptor 2
Protein-Tyrosine Kinase HEK5
EPTH3
HEK5
TYRO5
hEK5
EC 2.7.10
NCBI: 1p36.1-p35    Ensembl: 1p36.12
EPHB2_HUMANSize: 1055 amino acidsMass: 117493 Da

  • Subunit: Heterotetramer upon binding of the ligand. The heterotetramer is composed of an ephrin dimer and a receptor dimer. Oligomerization is probably required to induce biological responses (By similarity). Interacts (via PDZ-binding motif) with GRIP1 and PICK1 (via PDZ domain) (By similarity). Interacts with ARHGEF15; mediates ARHGEF15 phosphorylation, ubiquitination and degradation by the proteasome. Interacts with AQP1; involved in endolymph production in the inner ear 4 PDB 3D structures from [IMAGE] and Proteopedia [IMAGE] for EPHB2: 1B4F (3D) [IMAGE] 1F0M (3D) [IMAGE] 2QBX (3D) [IMAGE] 3ZFM (3D) [IMAGE]
  • Tissue specificity: Brain, heart, lung, kidney, placenta, pancreas, liver and skeletal muscle. Preferentially expressed in fetal brain [IMAGE] Pathway & Disease-focused RT2 Profiler PCR Arrays including EPHB2: TGFB Signaling Targets in human mouse rat Tumor Metastasis in hum
  • Function:
    Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Functions in axon guidance during development. Involved in the guidance of commissural axons, that form a major interhemispheric connection between the 2 temporal lobes of the cerebral cortex. Also involved in guidance of contralateral inner ear efferent growth cones at the midline and of retinal ganglion cell axons to the optic disk. Beside axon guidance, also regulates dendritic spines development and maturation and stimulates the formation of excitatory synapses. Upon activation by EFNB1, abolishes the ARHGEF15-mediated negative regulation on excitatory synapse formation. Controls other aspects of development including angiogenesis, palate development and in inner ear development through regulation of endolymph production. Forward and reverse signaling through the EFNB2/EPHB2 complex regulate movement and adhesion of cells that tubularize the urethra and septate the cloaca. May function as a tumor suppressor
                          
    Receptor tyrosine kinase which binds promiscuously transmembrane ephrin-B family ligands residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. The signaling pathway downstream of the receptor is referred to as forward signaling while the signaling pathway downstream of the ephrin ligand is referred to as reverse signaling. Functions in axon guidance during development. Involved in the guidance of commissural axons, that form a major interhemispheric connection between the 2 temporal lobes of the cerebral cortex. Also involved in guidance of contralateral inner ear efferent growth cones at the midline and of retinal ganglion cell axons to the optic disk. Beside axon guidance, also regulates dendritic spines development and maturation and stimulates the formation of excitatory synapses. Upon activation by EFNB1, abolishes the ARHGEF15-mediated negative regulation on excitatory synapse formation. Controls other aspects of development including angiogenesis, palate development and in inner ear development through regulation of endolymph production. Forward and reverse signaling through the EFNB2/EPHB2 complex regulate movement and adhesion of cells that tubularize the urethra and septate the cloaca. May function as a tumor suppressor
  • Catalytic activity:
    ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate
  • Similarity:
    Belongs to the protein kinase superfamily. Tyr protein kinase family. Ephrin receptor subfamily
                          
    Contains 1 Eph LBD (Eph ligand-binding) domain
                          
    Contains 2 fibronectin type-III domains
                          
    Contains 1 protein kinase domain
                          
    Contains 1 SAM (sterile alpha motif
  • Protein Domain/Family    
    Source ID Domain Name Type
    InterProIPR000719Prot_kinase_domProtein kinaseDomain
    IPR001090Ephrin_rcpt_lig-bd_domEphrin receptor, ligand bindingDomain
    IPR001245Ser-Thr/Tyr_kinase_cat_domTyrosine protein kinaseDomain
    IPR001426Tyr_kinase_rcpt_V_CSReceptor tyrosine kinase, class VFamily
    IPR001660SAMSterile alpha motif SAMDomain
    IPR003961Fibronectin_type3Fibronectin, type IIIDomain
    IPR008266Tyr_kinase_ASTyrosine protein kinase, active siteActive Sites
    IPR008979Galactose-bd-likeGalactose-binding likeDomain
    IPR009030Growth_fac_rcpt_N_domGrowth factor, receptorDomain
    IPR011009Kinase-like_domProtein kinase-likeDomain
    IPR011641Tyr-kin_ephrin_A/B_rcpt-likeGCC2 and GCC3Domain
    BlocksIPB001090Ephrin receptorEphrin receptor, ligand binding
    IPB001426Receptor tyrosine kinaseReceptor tyrosine kinase, class V
    IPB003962Fibronectin type III repeat signatureFibronectin type III repeat signature
    IPB008266Tyrosine protein kinaseTyrosine protein kinase, active site

    Gene Ontology    
    Type Term Evidence Source Pub
    Biological Process nervous system development TAS GOA 8589679
    Molecular Function protein binding IPI GOA 17255949
    transmembrane-ephrin receptor activity TAS GOA 8589679

    Disorder & Mutation    
    Source Disease
    SWISS-PROTProstate cancer (PC) [MIM:176807]: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. Note=The gene represented in this entry may be involved in disease pathogenesis. EPHB2 mutations have been found in a prostate cancer cell line derived from a brain metastasis

    EPHB2 cross reference    
    PubMed OMIM Entrez Gene NCKU SNP Nucleotide UniProt Genome Data Viewer HomoloGene